Cabozantinib

Cabozantinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Digestive System Neuroendocrine Tumor G1、Metastatic Digestive System Neuroendocrine Tumor G2、Unresectable Digestive System Neuroendocrine Tumor G1、Unresectable Digestive System Neuroendocrine Tumor G2。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Cabozantinib 研究

• Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer

  不适用招募中法国NCT04823923

• A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

  II 期招募中法国NCT04116541

• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

  II 期招募中美国NCT05361720

• Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

  II 期招募中美国NCT05931393

• A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)

  II 期招募中意大利NCT04893785

• Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

  I 期 / II 期招募中美国NCT06811116

• Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.

  IV 期招募中意大利NCT06903312

• A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

  II 期招募中美国NCT05048212

• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

  II 期招募中中国NCT06482086

• Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  III 期招募中丹麦芬兰法国意大利NCT07871864

• TDM for Optimized Outcome in Patients With mRCC.

  不适用招募中丹麦NCT04659343

• Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

  II 期招募中美国加拿大NCT05773274

• Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

  I 期招募中美国NCT06502171

• Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  I 期 / II 期招募中美国NCT03539822

• Cabozantinib to Treat Recurrent Liver Cancer Post Transplant

  II 期招募中加拿大NCT04204850

• A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  I 期 / II 期招募中美国Argentina澳大利亚加拿大NCT07293351

• A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  II 期招募中美国NCT05135975

• Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma

  IV 期招募中法国NCT06934057

• Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

  IV 期招募中法国NCT07028125

• Cabozantinib for Patients With Recurrent or Progressive Meningioma

  II 期招募中美国NCT05425004

• Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

  I 期招募中美国NCT04878029

• Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

  II 期招募中美国NCT06006013

• Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

  I 期招募中美国NCT07194044

• Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

  I 期 / II 期招募中美国NCT05559879

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。